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Abstract
Background: The objective of this study was to compare the efficacy and side effects of a single dose
(Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast
cancer patients in a non-inferiority clinical trial.
Methods: In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In
one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in
each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of
treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and
during eight cycles of chemotherapy.
Results: Hematologic parameters showed no significant differences in any of the treatment courses between the
two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575),
Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no
statistically significant difference between the two study groups. Side effects including headache, injection site
reaction and muscle pain had a lower frequency in patients receiving PDL drugs.
Conclusion: It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be
administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of
chemotherapy-induced neutropenia.
Trial registration: IRCT20190504043465N1, May 2019.
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Background
G-CSF is the main cytokine for the control of neutrophil
production that is clinically used for the treatment of
congenital and acquired neutropenia [1]. This cytokine
increases the number of circulating neutrophils in vitro
and improves their performance [2]. More than 90% of
patients respond to G-CSF by an increase of more than
1 × 109/L in ANC (Absolute Neutrophil Count) [3, 4].
These patients benefit greatly from G-CSF [4, 5]; for ex-
ample, by showing a significant improvement in their
quality of life, including health, performance in society
and socioeconomic status, a reduction in the frequency
and severity of infections, fever, use of antibiotics,
hospitalization and oral ulcers and an increased survival
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rate [5–12]. Furthermore, treating children with severe
congenital neutropenia reduces the risk of sepsis severely
[13]. This cytokine improves the quality of life of pa-
tients significantly. Treatment with rhG-CSF improves
all previous chronic infections, decreases the frequency
of new episodes of infection, and helps discontinue the
administration of prophylactic antibiotics [6]. Various
studies have been conducted on the side effects of G-
CSF. Increased spleen size has been reported as a side ef-
fect in most patients. Also, the effect of G-CSF on bone
marrow stimulation and development is manifested as early
bone pain [8]. According to the Severe Chronic Neutro-
penia International Registry (SCNIR), the side effects of
these patients include bone pain, splenomegaly,
thrombocytopenia, osteoporosis, and leukemia/MDS [4, 14]
as well as fever, myalgia, and erythema [15]. G-CSF has sev-
eral effects on the granulocytic cell line; not only does it
stimulate the growth and differentiation of myeloid precur-
sors, it also enhances the activity of adult neutrophils [16].
According to numerous studies, the side effects of this drug
include splenomegaly, thrombocytopenia, osteopenia and
osteoporosis, bone pain, vasculitis, skin rash, eosinophilia,
monocytosis and malignant changes to AML/MDS [2–4, 7,
10, 17–19]. Other studies with disparate findings have re-
ported symptoms such as hyperplasia, glomerulonephritis,
myalgia, erythema, dyspnea, hypotension, sweating, and hot
flashes [2, 15, 20]. The most important of these complica-
tions is the progress of MDS to AML, although it is still un-
clear whether G-CSF is the cause of this progression or if
the increased survival of congenital patients by G-CSF cre-
ates an opportunity for this transformation to take place be-
cause of the inherent tendency of MDS to progress towards
the congenital neutropenic disease called AML [21, 22].
Various cytogenetic abnormalities have been associated
with these malignancies; for example, CSF3R mutation (the
G-CSF receptor), ELA2 gene mutation, rascogenic activity,
chromosome 7 monosomy, and chromosomal changes.
These patients show resistance to G-CSF therapy and may
develop severe infections, which are often life-threatening.
These patients also often do not show good treatment out-
comes even after hematopoietic stem-cell transplantation
[3, 23, 24].
Most patients should take some kind of GCSF during
dose-dense treatments. If receiving treatment with PGL,
the patient should receive the drug every day after chemo-
therapy for at least six days, but if receiving PDL, only one
shot of the drug is required in each course of chemother-
apy. Therefore, the objective of this study is to compare
the effectiveness and side effects between the two drugs in
breast cancer patients in a non-inferiority clinical trial.
Methods
This interventional study compared the efficacy and safety
of PDL produced by Pooyesh Darou Biopharmaceuticals
Company with PDG in breast cancer patients as a non-
inferiority, parallel-group, randomized clinical trial. Fig-
ure 1 presents the flow diagram of the study.
Patients and criteria
This study was conducted on 80 patients diagnosed with
breast cancer and referred to Motamed Cancer Institute
for chemotherapy. They were treated with adjuvant and
neoadjuvant therapy with a dose-dense AC*4-T*4 regi-
men consisting of four courses of Adriamycin plus
Cyclophosphamide and four courses of Taxane-based
drugs.
The inclusion criteria were:
 Age > 18 years
 Investigator diagnosis of breast cancer and being a
candidate of adjuvant therapy
 Absolute neutrophil count ≥1.5 × 109/l
 Platelet count ≥100 × 109/l
 Serum creatinine < 1.5 × upper limits of normal
 Indication of receiving GCSF
The exclusion criteria consisted of:
 Bilirubin >upper limit of normal; or aspartate
transaminase and/or alanine transaminase > 1.5 ×
upper limits of normal, concomitant with alkaline
phosphatase > 2.5 × upper limit of normal
 Radiation therapy within 4 weeks of randomization
into this study
 Prior bone marrow or stem cell transplantation
 Total lifetime exposure to doxorubicin > 240 mg/m2
or epirubicin > 600 mg/m2
 Ejection fraction < 40%
 Liver cirrhosis
In the case of serious complications due to the use of
PDL, the patient was excluded from the study.
The eligible breast cancer patients who were under ad-
juvant and neoadjuvant chemotherapy with a dose-dense
AC*4-T*4 regimen signed informed consent forms and
entered the study. They were randomly assigned to the
drug group (PDL) or to the control group (PDG) and
their demographic and clinical characteristics were re-
corded. These drugs were administered to them free of
charge under the supervision of a physician at the treat-
ment center. Both groups received up to eight courses of
chemotherapy, the first four of which consisted of Adria-
mycin and the second four of taxane-based drugs.
Hematologic parameters and potential side effects of the
drug were recorded based on the patients’ blood cell
count and symptoms at baseline and on days 7 and 15
of each chemotherapy course.
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The incidence of febrile neutropenia in any cycle was
taken as a primary efficacy outcome. According to
Holmes’ study [25], the rate of success of PDL and PDG
in decreasing the incidence of neutropenia was 0.91 and
0.82, respectively. Considering the non-inferiority mar-
gin of 0.1, allocation ratio of 1/1, α error of 0.05, and
80% test power in this study, 40 patients were ultimately
examined.
The patients were trained to inform the researchers of
any complications they developed by calling the phone
numbers given in the consent form. If any patients had
fever and neutropenia in the first week or second week
after the treatment, at least three additional doses of ap-
propriate antibiotics were administered to them, and
they were admitted to the hospital upon the physician’s
advice. In patients with grade 3 or 4 of neutropenia,
PDL would change to PDG until the end of the treat-
ment and the patients were excluded from the PDL
group. If the patient was hospitalized, Pooyesh Darou
Biopharmaceuticals Company would incur all the treat-
ment costs.
Intervention
The patients in the PDL group received a single subcuta-
neous injection of 6 mg Pegfilgrastim on the second day
of each chemotherapy cycle. In the PDG group, in each
chemotherapy cycle, 300 micrograms Filgrastim per day
was injected subcutaneously for six consecutive days.
Outcome
The outcomes of interest were hematologic parameters,
including WBC,1 Hgb,2 Platelet, Neutrophil, Lymphocyte,
Fig. 1 The CONSORT flow diagram
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and ANC,3 and their values were compared between the
two groups in each of the eight courses of chemotherapy.
ANC was calculated by multiplying the percentage of neu-
trophils by the total number of WBCs (in thousands). The
short and long-term side effects of the drugs were re-
corded in both groups during the study.
Randomization and blinding
Randomization was performed using quadruple blocks.
The randomization blocks were pockets given by the
corresponding researcher. The blinding procedure was
supervised by a staff member of the clinic who was not
involved in the patients’ enrolment. The oncologist
assigned the participants to the interventions. Due to the
different administration protocols of the two drugs and
the need for the supervision of an oncologist, blinding
the patients and therapists was not possible. The statis-
tical analyst was also not informed about the assignment
of the patients to the groups.
Statistical analysis
An interim analysis was achieved after reaching one-
third of the sample size. Since no side effects were no-
ticed in the two groups, recruitment continued until the
end of the study. Descriptive statistics were used to
present the frequency of the demographic and clinical
characteristics in the two groups. The randomized allo-
cation of the participants into the two groups was
assessed using the Chi-square test and the student’s T-
test. The Kolmogorov-Smirnov test was applied to evalu-
ate the normality of the outcome variables’ distribution.
Most variables did not have a normal distribution and
nonparametric tests were therefore used in the next
steps of the analysis.
The mean and median of the distribution of the
hematologic variables (WBC, HgB, platelet, neutrophil,
lymphocyte, and ANC) and the frequency of complica-
tions were compared between the PDG and PDL groups.
Changes in hematologic variables from baseline until
days 7 and 15 in each course of chemotherapy were
evaluated in both groups using Friedman’s test. The vari-
ation in repeated measurements of the outcome was
compared between the two groups using Generalized Es-
timating Equation (GEE) analysis. The changes in the
hematologic parameters during the eight courses of
chemotherapy were compared between the two groups
using the GEE analysis as well. The statistical analyses of
the data were performed in SPSS software version 22.
Ethical considerations
The patients entered the study by signing a written in-
formed consent for drug intake. All information such as
emphasizing the process of implementation, the right to
withdraw from the study during the treatment, covering
expenses, possible side effects and an emergency phone
number for consultation and reporting side effects were
included in the informed consent form. This research
was approved by the Ethics Committee of the Breast
Cancer Research Center with the code: IR.ACECR.IBCR-
C.REC.1395.19. The research project was also registered
at the Iranian Registry of Clinical Trials (IRCT) in
https://www.irct.ir/ with the registration code:
IRCT20190504043465N1.
Results
Eighty breast cancer patients were equally allocated to
the PDL and PDG groups. Table 1 compares the demo-
graphic and clinical characteristics of the patients treated
by PDG or PDL. The mean age of the PDG and PDL
groups was 47.8 ± 9.04 and 43.7 ± 9.23, respectively.
There was no significant difference between the two
groups in terms of age, BMI,4 tumor size, excised LN,5
involved LN, Ki-67 index, education, marital status, em-
ployment status, ER,6 PR,7 and HER2.8
Outcome measurements were achieved at baseline and
on days 7 and 15 in each course of chemotherapy.
Table 2 presents the distribution of the hematologic var-
iables in the eight courses of chemotherapy in both
groups.
Figure 2 shows the changes in ANC values during the
eight courses of chemotherapy in the PDG and PDL
groups. Similar trends of ANC values are noticeable be-
tween the two groups.
The within- and between-groups variations in blood
count were analyzed at baseline and on days 7 and 15 in
each course of chemotherapy (Table 3). The results sug-
gest that, in both the PDL and PGL groups, all the
hematologic components (WBC, Hgb, Plt, Neut, Lymph
and ANC) changed significantly during each course of
chemotherapy. A reduction in the hematologic compo-
nent and its increase after GCF injection was the prom-
inent pattern of data variations in each course.
Nonetheless, in the fifth course of PDL injection, Hgb
showed no significant changes (P = 0.095).
Applying GEE analysis showed no significant differ-
ences between the trend of hematologic values during








8Human Epidermal Growth Factor Receptor 2
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exceptions in the third course of chemotherapy, during
which the neutrophil count (p = 0.023) and lymphocyte
count (p = 0.006) had lower fluctuations in the PDL
group.
The changes in hematologic parameters during the
eight courses of chemotherapy were compared between
the two groups using GEE analysis. The comparison of
the WBC (p = 0.527), Hgb (p = 0.075), platelet (p =
0.819), neutrophil (p = 0.575), lymphocyte (p = 705) and
ANC (p = 0.675) changes during the eight courses of
treatment identified no statistically significant differences
between the two study groups.
Since the probability of neutropenia frequency fluctuates
during treatment, the changes in blood parameters were
compared between the first four courses of chemotherapy
and the second four courses. In the PDG group, the mean
values of WBC, Plt, and ANC in the first half of treatment
were 6281, 153,171, and 3358, and in the second half, they
were 6280, 151,064 and 5220, respectively. The P-value
for the mean difference in WBC, Plt and ANC between
the two treatment halves was < 0.001, 0.543 and < 0.001.
In the PDL group, the mean values of WBC, Plt, and ANC
in the first half of the treatment were 4446, 154,095 and
3249, and in the second half, they were 6820, 152,298 and
5575, respectively. The P-value for the mean difference in
WBC, Plt and ANC between the two treatment halves was
< 0.001, 0.651 and < 0.001.
The results showed that the changes in WBC (p =
0.439), Hgb (p = 0.052), platelet (p = 0.7), neutrophil (p =
0.324), lymphocyte (p = 0.463) and ANC (p = 0.571) dur-
ing the two halves of treatment did not differ signifi-
cantly between the two study groups.
Table 4 presents a comparison of the side effects be-
tween the two groups. There was no side effect in 50%
Table 1 The demographic and clinical characteristics of the patients in the two study groups
Variable PDG PDL P-value
Mean ± SD Mean ± SD
Age, year 47.8 ± 9.04 43.7 ± 9.23 0.05
BMI, kg/m2 27.8 ± 4.88 26.6 ± 4.06 0.261
Tumor size, cm 3.0 ± 1.1 3.1 ± 0.9 0.744
Excised LN, n 7.9 ± 4.6 8.7 ± 6.1 0.566
Involved LN, n 2.1 ± 2.7 2.1 ± 2.6 0.958
Ki-67, % 36.0 ± 23.2 34.6 ± 26.5 0.819
No (%) No (%)
Age 0.116
< 50 24 (60) 30 (75)
≥ 50 16 (40) 10 (25)
Education 0.362
Illiterate/Primary School 16 (42.1) 19 (48.7)
High School Diploma/University Education 22 (57.9) 20 (51.3)
Marital status 0.387
Married 33 (82.5) 33 (87.5)
Single/Divorced/Widowed 7 (17.5) 5 (12.5)
Employment status 0.293
Housewife 30 (75.5) 33 (82.5)
Employed 10 (25) 7 (17.5)
ER 0.150
Negative 11 (28.2) 6 (15.8)
Positive 28 (71.8) 32 (84.2)
PR 0.061
Negative 19 (48.7) 11 (28.9)
Positive 20 (51.3) 27 (71.1)
HER2 0.587
Negative 31 (79.5) 30 (78.9)
Positive 8 (20.5) 8 (21.1)
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Baseline WBC 9068.42 ± 1433.59 8361.58 ± 1992.03
Hgb 12.75 ± 1.04 12.98 ± 1.2
Platelet 298,972.22 ± 130,889.81 281,910.53 ± 104,249.08
Neutrophil 74.5 ± 6.62 75.37 ± 6.09
Lymphocyte 24.97 ± 6.38 22.92 ± 6.92
ANC 6659 ± 1263 6388 ± 1682
1st course (day 7) WBC 3623.68 ± 1272.46 5997 ± 12,404
Hgb 12.56 ± 1.01 12.8 ± 1.01
Platelet 141,722.22 ± 77,288.18 136,584 ± 32,865
Neutrophil 46.5 ± 6.19 47.6 ± 6.3
Lymphocyte 52.97 ± 6.57 51.3 ± 6.6
ANC 1662 ± 737 2896 ± 6062
1st course (day 15) WBC 5618.42 ± 1216.74 5827.63 ± 1127.22
Hgb 12.52 ± .95 12.76 ± 1.107
Platelet 182,694.44 ± 35,740.19 185,578.95 ± 32,961.59
Neutrophil 85.18 ± 5.4 84.66 ± 5.54
Lymphocyte 14.45 ± 4.75 15 ± 5.57
ANC 4655 ± 1292 4891 ± 1054
2nd course (day 7) WBC 2786.84 ± 850.17 3553.16 ± 3202.25
Hgb 12.36 ± 1.03 12.44 ± 1.06
Platelet 109,055.55 ± 19,608.95 117,118.42 ± 20,749.29
Neutrophil 47.71 ± 6.21 50.52 ± 8.98
Lymphocyte 51.23 ± 6.09 48.21 ± 10.82
ANC 1324 ± 476 1819 ± 1891
2nd course (day 15) WBC 5405.52 ± 5803.10 4693.42 ± 831.65
Hgb 12.25 ± .96 12.4 ± 1.18
Platelet 152,444.44 ± 12,622.98 160,131.58 ± 20,145.64
Neutrophil 86.73 ± 5.75 86.34 ± 4.39
Lymphocyte 14.02 ± 8.14 12.89 ± 3.67
ANC 4550 ± 4351 4009 ± 808
3rd course (day 7) WBC 2610.52 ± 1345.12 2660.52 ± 1277.09
Hgb 12.14 ± .93 15.23 ± 17.99
Platelet 97,802.78 ± 14,290.07 103,476.31 ± 132,901.69
Neutrophil 47.4 ± 6.9 51.18 ± 4.57
Lymphocyte 51.97 ± 6.52 47.55 ± 5.25
ANC 1215 ± 582 1359 ± 636
3rd course (day 15) WBC 3961.31 ± 668.86 3993.68 ± 717.65
Hgb 12.06 ± .92 15.14 ± 17.99
Platelet 142,861.11 ± 14,204.93 145,589.47 ± 27,305.87
Neutrophil 87.1 ± 5.05 87.87 ± 4.47
Lymphocyte 12.81 ± 5.11 12 ± 4.6
ANC 1864 ± 431 2010 ± 450
4th course (day 7) WBC 2284.47 ± 1369.58 1976.58 ± 380.76
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Hgb 11.92 ± .92 12.07 ± .84
Platelet 90,383.33 ± 28,554.37 92,842.1 ± 11,083.29
Neutrophil 49.1 ± 10.91 50.26 ± 4.92
Lymphocyte 50.29 ± 10.68 47.68 ± 6.63
ANC 1148 ± 881 3711 ± 968
4th course (day 15) WBC 4213.15 ± 4968.81 3415.79 ± 789.98
Hgb 11.61 ± 1.95 11.98 ± .78
Platelet 131,355.55 ± 27,377.83 134,000 ± 27,496.44
Neutrophil 86.52 ± 7.29 86.79 ± 4.89
Lymphocyte 13.34 ± 7.21 13.08 ± 4.74
ANC 3563 ± 3892 996 ± 222
5th course (7th day) WBC 2593.42 ± 538.79 2455.52 ± 688.89
Hgb 11.78 ± .93 11.93 ± .79
Platelet 104,027.78 ± 12,112.53 100,473.68 ± 29,235.82
Neutrophil 50.53 ± 6.55 52.63 ± 5.54
Lymphocyte 47.79 ± 9.516 46.55 ± 6.41
ANC 1312 ± 360 1299 ± 406
5th course (15th day) WBC 5339.47 ± 1450.54 5121.08 ± 1699.03
Hgb 11.68 ± .96 11.89 ± .76
Platelet 153,888.89 ± 21,372.58 158,657.89 ± 42,731.9
Neutrophil 88.24 ± 6.32 88.58 ± 4.18
Lymphocyte 11.63 ± 6.41 10.87 ± 3.4
ANC 4681 ± 1328 4554 ± 1597
6th course (7th day) WBC 3515.79 ± 701.65 3531.58 ± 889.23
Hgb 11.6 ± 1.03 11.85 ± .71
Platelet 118,111.11 ± 22,193.66 116,078.95 ± 17,653.4
Neutrophil 51.66 ± 6.84 52.6 ± 6.82
Lymphocyte 47.55 ± 7.03 46.95 ± 7.17
ANC 1809 ± 460 1879 ± 755
6th course (15th day) WBC 7200 ± 1567.23 7056.58 ± 1948.95
Hgb 11.58 ± .9 11.76 ± .72
Platelet 173,972.22 ± 19,983.54 171,236.84 ± 37,220.62
Neutrophil 88.73 ± 5.23 88.37 ± 3.97
Lymphocyte 11.13 ± 5.2 11.63 ± 3.97
ANC 6371 ± 1558 6244 ± 1792
7th course (7th day) WBC 5722.37 ± 7130.64 4190.79 ± 757.38
Hgb 11.52 ± .88 11.69 ± .73
Platelet 124,611.11 ± 15,331.16 122,815.79 ± 16,204.53
Neutrophil 52.87 ± 5.5 68.34 ± 98.78
Lymphocyte 46.34 ± 5.82 46.18 ± 8.47
ANC 3086 ± 4284 2923 ± 4491
7th course (15th day) WBC 11,797.37 ± 14,999.43 8007.9 ± 2431.03
Hgb 11.48 ± .95 11.63 ± .76
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of the patients in the PDL group compared to 12.5% in
the PDG group. The most common side effects in the
PDG group were musculoskeletal pain, with a relative
frequency of 47.5%, compared to 15% in the PDL group.
Headache (30%), injection site reaction (25%),
leukocytosis (20%), and bone pain (17.5%) were other
common side effects in the PDG group.
Three patients were excluded from the study. In the
PDL group, two patients were excluded from the study
because of fever and neutropenia. The first patient re-
ceived PDL in two courses of chemotherapy. In the third
course, ANC decreased to 490 on the 7th day of the in-
jection. In the second case in this group, an ANC of 750
was recorded at the end of the third course of





Platelet 183,500 ± 21,285.14 181,289.47 ± 31,302.28
Neutrophil 89.44 ± 4.85 90.63 ± 3.83
Lymphocyte 9.05 ± 3.38 10.64 ± 10.17
ANC 10,515 ± 13,354 7273 ± 2273
8th course (7th day) WBC 5396.05 ± 1612.13 5010.53 ± 945.41
Hgb 11.15 ± 1.91 11.51 ± .81
Platelet 128,583.33 ± 20,230.63 127,594.74 ± 17,224.53
Neutrophil 53.55 ± 6.03 52.21 ± 7.29
Lymphocyte 45.39 ± 8.08 46.63 ± 7.65
ANC 2924 ± 1057 2624 ± 648
8th course (15th day) WBC 13,300 ± 6704.21 13,448.68 ± 17,942.84
Hgb 11.52 ± 1.24 11.41 ± .87
Platelet 193,444.44 ± 26,144.04 194,526.31 ± 41,315.36
Neutrophil 88.94 ± 7.64 90.05 ± 4.77
Lymphocyte 10.68 ± 7.39 9.71 ± 4.79
ANC 11,861 ± 6426 12,133 ± 16,165
Fig. 2 Changes in ANC values during the eight courses of chemotherapy in the two groups
Najafi et al. BMC Cancer          (2021) 21:454 Page 8 of 12
Table 3 Comparing the within- and between-group blood counts measured at baseline and on days 7 and 15 in each course of
chemotherapy
Courses PDL Group (Median) p-
value*
PGL Group (Median) p-
value*
p-
value**D0 D7 D15 D0 D7 D15
1 WBC 8900 4100 5850 < 0.001 9550 3850 5750 < 0.001 0.295
Hb 13.20 13.00 13.00 < 0.001 12.80 12.35 12.25 < 0.001 0.159
Plt 280,000 124,000 173,000 < 0.001 248,500 124,000 168,000 < 0.001 0.416
Neut 75 50 85 < 0.001 70 50 85 < 0.001 0.312
Lymph 25 50 15 < 0.001 27 50 15 < 0.001 0.130
ANC 6545 2050 5025 < 0.001 6830 1660 4600 < 0.001 0.327
2 WBC 5850 3100 4400 < 0.001 5750 3000 4500 < 0.001 0.866
Hb 13.00 13.00 12.90 < 0.001 12.25 12.20 12.20 < 0.001 0.307
Plt 173,000 111,000 156,000 < 0.001 168,000 107,000 156,000 < 0.001 0.468
Neut 85 50 85 < 0.001 85 50 86 < 0.001 0.504
Lymph 15 50 13 < 0.001 15 50 14 < 0.001 0.243
ANC 5025 1575 3838 < 0.001 4600 1400 3895 < 0.001 0.950
3 WBC 4400 2450 3950 < 0.001 4500 2500 3950 < 0.001 0.820
Hb 12.90 12.90 12.30 < 0.001 12.20 12.00 12.00 < 0.001 0.107
Plt 156,000 101,000 139,000 < 0.001 156,000 100,000 146,000 < 0.001 0.302
Neut 85 50 90 < 0.001 86 50 90 < 0.001 0.023
Lymph 15 50 10 < 0.001 14 50 10 < 0.001 0.006
ANC 3838 1305 1975 < 0.001 3895 1200 1900 < 0.001 0.229
4 WBC 3950 1900 3100 < 0.001 3950 2100 3400 < 0.001 0.443
Hb 12.30 12.05 12.05 < 0.001 12.00 12.00 12.00 < 0.001 0.473
Plt 139,000 92,500 128,500 < 0.001 146,000 98,000 132,000 < 0.001 0.969
Neut 90 50 90 < 0.001 90 50 90 < 0.001 0.317
Lymph 10 50 11 < 0.001 10 50 10 < 0.001 0.143
ANC 1975 955 2738 < 0.001 1900 1020 2872 < 0.001 0.548
5 WBC 3100 2500 4500 < 0.001 3400 2500 4900 < 0.001 0.341
Hb 12.05 12.00 12.00 0.095 12.00 12.00 11.50 < 0.001 0.237
Plt 128,500 100,000 151,000 < 0.001 132,000 102,000 159,000 < 0.001 0.974
Neut 90 50 90 < 0.001 90 50 90 < 0.001 0.413
Lymph 11 50 10 < 0.001 10 50 10 < 0.001 0.590
ANC 2738 1350 3895 < 0.001 2872 1250 4410 < 0.001 0.289
6 WBC 4500 3200 6750 < 0.001 4900 3450 6800 < 0.001 0.581
Hb 12.00 12.00 12.00 0.001 11.50 11.40 11.30 < 0.001 0.206
Plt 151,000 111,500 159,500 < 0.001 159,000 110,000 174,000 < 0.001 0.919
Neut 90 50 90 < 0.001 90 50 90 < 0.001 0.663
Lymph 10 50 10 < 0.001 10 50 10 < 0.001 0.743
ANC 3895 1725 5948 < 0.001 4410 1900 6120 < 0.001 0.543
7 WBC 6750 4200 8400 < 0.001 6800 4600 9100 < 0.001 0.050
Hb 12.00 11.90 11.50 < 0.001 11.30 11.30 11.30 0.002 0.342
Plt 159,500 121,000 170,500 < 0.001 174,000 124,000 186,000 < 0.001 0.559
Neut 90 50 90 < 0.001 90 50 90 < 0.001 0.306
Lymph 10 50 10 < 0.001 10 50 10 < 0.001 0.898
ANC 5948 2100 7560 < 0.001 6120 2300 8330 < 0.001 0.146
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chemotherapy. Antibiotics were administered to both
patients out-patiently, and PDL was not continued for
them. As for the PDG group, one patient from this
group was hospitalized because of fever and neutropenia
after one course of injection. Her ANC in the first
course of chemotherapy decreased from 5440 to 70 dur-
ing 15 days of injection. She had oral mucositis and a
high grade of fever. She recovered after three days of
antibiotic therapy in the hospital.
Discussion
All the chemotherapy regimens used in this study con-
sisted of chemotherapy drugs that cause more than 10%
neutropenia without GCF. The chemotherapeutic agents
used in the study had eight courses. The first four
courses were completely similar and composed of Doxo-
rubicin and Cyclophosphamide, which cause neutro-
penia and fever more frequently. The next four courses
consisted of only Docetaxel, which is much less likely
than the previous courses to cause neutropenia. The re-
sults showed that the changes in WBC (p = 0.439), Hgb
(p = 0.052), platelet (p = 0.7), neutrophil (p = 0.324),
lymphocyte (p = 0.463) and ANC (p = 0.571) during the
two halves of treatment did not differ significantly be-
tween the two study groups. The changes in hematologic
parameters during the eight courses of chemotherapy
did not show any statistically significant differences be-
tween the two study groups.
Several studies have proven the efficacy of PDG as a
drug. Due to the number of daily injections of the drug,
PDG was released slowly. The PEGylated form of this
drug has been effective and safe according to clinical
trial studies. The PEGylation of drugs improves their
clinical value; for instance, it increases their solubility
[26], protects them against enzyme degradation [27], de-
creases their renal clearance [28], causes physical and
thermal stability [29], and increases the antigenicity and
toxicity half-life [30]. PDL is a G-CSF quadrilateral con-
jugate formulation whose efficacy and safety are compar-
able with PDG [31–33]. The half-life of PDL is 12 times
longer than the half-life of non-conjunctive drugs. Poly-
ethylene glycol binding to G-CSF reduces renal secretion
and prevents its proteolysis, resulting in an increase in
drug levels up to 14 days after single-dose administra-
tion. Following regular chemotherapy regimens, the
number of leukocytes and the appearance of CD34 in
the peripheral blood occur faster and sooner after PDL
than G-CSF [34]. PDG has been used in chemotherapy-
induced neutropenic patients and has recently been used
to treat children’s neutropenia as well [32]. In a study by
Holmes et al. in 2002, in which 154 female breast cancer
patients were enrolled, 129 patients received PDL and
25 received G-CSF. Five patients had unbearable side ef-
fects that resulted in the discontinuation of the drug;
one of these patients developed renal insufficiency with
a dose of 100 micrograms per kilogram, and four others
developed the following side effects with a dose of at
least 30 micrograms: Fever, diarrhea, nausea and dehy-
dration. Other side effects observed in all the patients
were mild to moderate bone pain similar to PDL and G-
CSF (35%), and 7% of the patients needed to use nar-
cotics to relieve their pain [24]. There was no side effect
Table 3 Comparing the within- and between-group blood counts measured at baseline and on days 7 and 15 in each course of
chemotherapy (Continued)
Courses PDL Group (Median) p-
value*
PGL Group (Median) p-
value*
p-
value**D0 D7 D15 D0 D7 D15
8 WBC 8400 4950 10,000 < 0.001 9100 5100 10,550 < 0.001 0.395
Hb 11.50 11.35 11.35 < 0.001 11.30 11.25 11.25 < 0.001 0.528
Plt 170,500 124,000 186,500 < 0.001 186,000 124,000 194,500 < 0.001 0.637
Neut 90 50 90 < 0.001 90 50 90 < 0.001 0.781
Lymph 10 50 10 < 0.001 10 50 10 < 0.001 0.838
ANC 7560 2525 9000 < 0.001 8330 2575 9601 < 0.001 0.434
P-value*: Repeated measurements within the groups (Friedman’s test)
P-value**: Repeated measurements between the groups (GEE analysis)








No 5 (12.5) 20 (50%) 25 (31.25)
Headache 24 (30) 10 (25) 34 (42.5)
Bone pain 7 (17.5) 3 (7.5) 10 (12.5)
Nausea 3 (7.5) 4 (10) 7 (8.75)
Musculoskeletal pain 19 (47.5) 6 (15) 25 (31.25)
Fever – 1 (2.5) 1 (1.25)
Injection site reaction 10 (25) 1 (2.5) 11 (13.75)
Leukocytosis 8 (20) 4 (10) 12 (15)
Non-cardiac chest pain 1 (2.5) – 1 (1.25)
Anaphylaxis 1 (2.5) – 1 (1.25)
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in 50% of the patients in the PDL group compared with
12.5% in the PDG group. Also, the most common side
effects in the PDG group were musculoskeletal pain,
with a 47.5% frequency compared to 15% in the PDL
group, followed by injection site reaction, with a 25%
frequency in the PDG group. Headache (30% vs. 25%),
injection site reaction (25% vs. 2.5%), leukocytosis (20%
vs. 10%), and bone pain (17.5% vs. 7.5%) were other
common side effects in the PDG group. Since toxicity
grades I and II do not change the treatment protocol
and stratified analysis based on different grades of ad-
verse effects would greatly increase the sample size,
making a trial unfeasible, we considered grade-III and IV
toxicities as positive side effects.
In a study conducted on 310 adjuvant chemotherapy
patients taking 75 mg Docetaxel daily and 60mg Doxo-
rubicin per square meter of body surface area on the
first day of each cycle for a maximum of four cycles, the
patients who received 100 micrograms per kilogram of
weight PDL were compared with the patients who re-
ceived 5 micrograms per kilogram of weight PDG on the
second day of the cycle were compared with each other.
The results were almost similar in the two groups, and
the ANC values were not significantly different between
the two groups, and neutropenia with fever was less
common in the patients who took PDL. PDL was toler-
ated and the side effect profile of the two groups was
similar [25]. In another study randomly comparing mul-
tiple doses of PDL with filgrastim in breast cancer pa-
tients, a PDL dose of 100 micrograms per kilogram of
weight had good efficacy and a favorable side effect pro-
file [24]. In a double-blind, phase-III trial with a fixed 6-
mg dose of PDL, febrile neutropenia was less common
than G-CSF (13% vs. 20%) [3]. Any chemotherapeutic
regimen can cause neutropenia, but when the absolute
neutrophil count reaches below 1000, there is a very
high risk of febrile neutropenia and sepsis. Therefore,
most researchers believe that GCF should be used to
prevent a reduction in absolute neutrophil count to
below 1000.
In a study carried out on women receiving chemother-
apy during pregnancy who were administered G-CSF
and PDL, there were no significant changes in the gesta-
tional age at delivery, embryonic anomalies or the birth
weight of the baby; in these patients, myelopoiesis
stopped at the first stage of growth (the promyelocyte/
myelocyte stage) [17]. In a study by Calderwood et al. in
2001, splenomegaly was reported in all the patients while
mild hyperplastic hypertrophy was observed in a few,
and no short-term drug toxicity was reported for them
[2]. The results of this study using the diagram of trend
of changes in ANC and platelet count and lymphocyte
count as the main indicators of the effectiveness of drugs
showed no significant differences between the two
groups. In this study, despite the various side effects re-
corded for the drug, headache, bone pain and injection
site reaction were the most important and common side
effects, which showed the highest frequency in both
groups. Therefore, future studies on the subject are rec-
ommended to investigate these particular side effects.
Conclusion
PDL is completely non-inferior in efficacy and also less
toxic than PDG. Its prescription as a single-dose drug
that is also less expensive makes it a cost-effective treat-
ment for chemotherapy-induced neutropenia.
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